期刊文献+

法舒地尔治疗冠心病心绞痛临床疗效观察 被引量:2

下载PDF
导出
摘要 目的观察法舒地尔注射剂对冠心病心绞痛的临床疗效。方法选择符合标准的冠心病心绞痛患者93例,随机分两组,两组均予吸氧、抗血小板聚集、扩冠、抗凝等常规治疗,治疗组加用法舒地尔注射液60 mg加入生理盐水或5%葡萄糖注射液100ml静脉输注,每日2次。两组均治疗14 d。结果治疗组心绞痛疗效总有效率为89.4%、心电图疗效总有效率为89.4%,均优于对照组的65.2%、63.1%(P<0.01)。治疗组治疗后心绞痛发作次数较对照组明显减少(P<0.01),无不良反应。结论法舒地尔注射剂治疗冠心病心绞痛安全、有效,可降低心绞痛的发生。
出处 《右江医学》 2009年第6期657-658,共2页 Chinese Youjiang Medical Journal
  • 相关文献

参考文献6

  • 1张嘉莹,朱中玉,李牧蔚,陈岩,王现青.青年急性心肌梗死患者脂蛋白(a)水平的变化及其意义[J].临床心血管病杂志,2002,18(10):500-502. 被引量:248
  • 2Potteaux S, Esposito B, van Oostrom O, et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout micer[ J]. Arterioscler Thromb Vasc Biol,2004 Aug,24(8) : 1474- 1478.
  • 3Nagumo H, Sasaki Y, Ono Y, et al. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells[J]. Am J Physiol Cell Physiol, 2000 Jan, 278 ( 1 ) : C57 -65.
  • 4Otsuka T, Ibuki C, Suzuki T, et al. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris[J]. Circ J, 2006 Apr, 70 (4) : 402 - 408.
  • 5Masumoto A,Mohri M,Shimokawa H,et al. Suppression of coronary artery spasm by the Rb.o-kinase inhibitor fasudil in patients with vasospastic angina[J]. Circulation, 2002 Apr 2,105 (13) : 1545-1547.
  • 6Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil,a Rho-kinase inhibitor, in patients with stable effort angina : a multicenter study[J]. J Cardiovasc Pharmacol,2002 Nov,40 (5) :751-751.

二级参考文献7

  • 1Luc G, Bard J M, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis, 2001,163(2):377-384.
  • 2Seman L G, Deluca C, Jenner J L,et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem, 1999,45(7):1039-1046.
  • 3Lundstam U, Herlitz J, Karlsson T, et al. Serum lipids, lipoprtein (a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med, 2002,251(2):111-118.
  • 4Marcovina S M, Hegele R A, Koschinsky M L. Lipoprotein (a) and coronary heart disease risk. Curr Cardiol Rep,1999,1(2):105-111.
  • 5Angles C E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Braz J Med Biol Res,1997,30(11):1271-1280.
  • 6Maeda S, Abe A, Seishima M, et al. Transient change of serum lipoprotein (a) as an acute phase protein. Atherosclerosis, 1989,78(1):145-150.
  • 7Greory Y H, Gordon D L. Fibrin D-dimer: A useful marker of thrombogenesis? Clini Sci,1995(89):205-214.

共引文献247

同被引文献5

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部